You are here: Home » Asthma » Buy Advair Diskus (Adoair) online

Buy Advair Diskus (Adoair) online

21.01.2015 |

Discount 10%: rd-3142.

>>> Buy now ADVAIR DISKUS <<<
advair diskus

Analog: Asthma.

Name: Seretide Discus

Pharmachologic effect

Advair Diskus is an antiasthmatic combined preparation. Advair Diskus contains salmeterol and fluticasone.
Salmeterol is a long-acting selective beta2-adrenoceptor. Salmeterol effectively prevents the development of bronchospasm, inducted with histamine. The action of salmeterol lasts up to 12 hours.
Fluticasone propionate is a glucocorticosteroid drug substance. Fluticasone with an inhalation application has a pronounced anti-inflammatory effect on the lungs. Fluticasone provides a reduction in the severity of asthma exacerbation symptoms without the development of undesirable effects characteristic of systemic glucocorticosteroids.

The use of the complex preparation Advair Diskus allows to achieve “good control” and “full control” for the symptoms of asthma more effectively than monotherapy with glucocorticosteroids. When using combination therapy with salmeterol and fluticasone, the level of exacerbations is 29% lower than with monotherapy with glucocorticosteroids.
Advair Diskus reduces the need for rapid bronchodilators, reduces the number of exacerbations of asthma and improves the quality of life in patients with asthma.
In the combined use of salmeterol and fluticasone, the pharmacokinetic profile of these substances is similar to that of a separate application.

Advair Diskus acts locally and, when inhaled, practically does not enter the systemic circulation. Advair Diskus is not cumulated in the body, after 12 months after the start of therapy there is no increase in the plasma level of salmeterol. When using salmeterol xinafoate in the blood plasma, hydroxyanaphthoic acid is determined (the concentration is not more than 100 ng / ml).
Fluticasone propionate is slightly absorbed into the systemic blood stream when inhaled. Absolute bioavailability of fluticasone reaches 10-30%. The rest of the inhalation dose is swallowed, oral bioavailability of fluticasone reaches 1% (due to low solubility of the substance in the water and presystemic metabolism). With increasing doses, there is a linear increase in the systemic effect of fluticasone. The final half-life of fluticasone reaches 8 hours. About 91% of the substance binds to plasma proteins. Fluticasone is metabolized by the cytochrome P450 3A4 system and excreted mainly by the kidneys.

Indications for use
Advair Diskus is used for the regular treatment of reversible obstructive diseases of the respiratory system, including asthma in adults and children (in cases where combined therapy with an inhaled corticosteroid and bronchodilator is required).
Advair Diskus is prescribed to patients receiving effective maintenance doses of selective long-acting beta2-adrenomimetics and inhaled corticosteroids.
Advair Diskus is used in patients who, against the background of monotherapy with glucocorticosteroids, have symptoms of obstructive airway disease, as well as patients receiving bronchodilators who require the appointment of corticosteroids for inhalation.
Advair Diskus can be used as a basic therapy for patients suffering from chronic obstructive pulmonary diseases, including emphysema and chronic bronchitis.

Mode of application
Advair Diskus is intended for inhalation. It is recommended to use Advair Diskus regularly, including during the absence of asthma attacks. In the treatment of reversible obstructive diseases of the respiratory system, sequential regimens should be used and the patient’s condition monitored on a regular basis. At each reception, the prescribed dose should be reviewed and, if possible, reduced (the minimum effective dose of Advair Diskus should be selected). It is forbidden to change the dose of Advair Diskus without consulting a doctor.
For inhalation, you should open and charge the plastic device included in the kit by changing the position of the lever. The mouthpiece is wrapped around the lips, inhaled and closes the device. The dose indicator in the Disk shows the number of remaining doses.

The duration of application and dose of the drug Advair Diskus is determined by the doctor. At the beginning of therapy, as a rule, it is necessary to use the drug twice a day to control the symptoms, after achieving full control of asthma, the drug is used once a day. The amount of fluticasone in the drug is determined by the doctor, given the patient’s condition and the tolerability of the drug Advair Diskus.
With insufficient control of asthma with monotherapy with glucocorticosteroids, the purpose of the drug Advair Diskus allows to achieve an improvement in the condition without increasing the dose of corticosteroids. In patients with good asthma control when using glucocorticosteroid monotherapy, the appointment of Advair Diskus helps to reduce the dose of corticosteroid without loss of effect.

Average recommended doses for patients with reversible obstructive airways disease (including asthma):
Adults and adolescents are usually prescribed 1 dose of Advair Diskus 50 μg / 100 μg or Advair Diskus 50 μg / 25 μg or Advair Diskus 50 μg / 500 μg twice daily. Adults, if necessary, short-term (less than 2 weeks) corticosteroid maintenance therapy may be given 2 doses of Advair Diskus twice a day (safety and tolerability profile will be similar to that for prolonged use of 1 dose of Seretide Diskus twice a day).
Children older than 4 years are usually prescribed 1 dose of Advair Diskus 50 μg / 100 μg twice a day.

Average recommended doses for chronic obstructive pulmonary diseases (including emphysema and chronic bronchitis):
The dose is selected individually. The maximum permissible daily intake for adults is 2 doses of Seretide Diskus 50 μg / 500 μg (divided into 2 doses).
There is no need to adjust the dose of Advair Diskus for patients with impaired renal and hepatic function, as well as elderly patients.

In acute conditions it is necessary to use high-speed bronchodilators. It should be borne in mind that an increase in the frequency of use of high-speed bronchodilators for the relief of acute symptoms indicates a worsening of asthma control.
Progressive and rapid deterioration of asthma control can be potentially unsafe for life. If the prescribed dose of Advair Diskus does not allow you to fully control the symptoms or the number of seizures increases, you should consult your doctor.
The discontinuation of Advair Diskus should be carried out gradually both with short-term therapy and with prolonged use of the drug.
When prescribing Advair Diskus, children and adolescents should regularly monitor growth dynamics.
When switching from oral glucocorticosteroid therapy to inhalation therapy, adrenal function should be monitored.

Side effects
When using Advair Diskus, paradoxical bronchospasm may develop with immediate increase in dyspnea after inhalation. This condition requires immediate application of bronchodilators of fast and short action. After cupping the paradoxical bronchospasm, you should abolish Advair Diskus, examine the patient and prescribe an alternative therapy.

When using Advair Diskus in patients, it is possible to develop unwanted effects caused by fluticasone and salmeterol, including:
From the vessels and the heart: a feeling of palpitation, arrhythmia (including atrial fibrillation, extrasystole and supraventricular tachycardia).
From the nervous system: tremor of the limbs, headache, muscle spasms, sleep disorders, hyperactivity, unreasonable anxiety.
Allergic reactions: urticaria, bronchospasm, angioedema, anaphylactic shock.
others: arthralgia, hyperglycemia.

Possible development of hoarseness, irritation and / or candidiasis of the mucous membrane of the pharynx and oral cavity, the risk of development of which decreases when rinsing the mouth and throat with water after each use of the inhaler. Treatment of symptomatic candidiasis is carried out by local means, without stopping the use of the drug Advair Diskus.
With prolonged use of high doses of Advair Diskus in patients, it is possible to develop systemic effects of fluticasone. In particular, it is impossible to exclude the development of Cushing’s syndrome, Cushingoid signs, growth retardation in children, as well as cataracts, glaucoma and bone mineralization disorders.

Contraindications
Advair Diskus is not prescribed to patients with a history of hypersensitivity reactions to fluticasone, salmeterol or an additional component of the drug.
Advair Diskus is not used for relief of acute symptoms, which require the use of high-speed bronchodilators.
Advair Diskus should be administered with caution to patients suffering from latent and active pulmonary tuberculosis, thyrotoxicosis and diabetes mellitus.

Advair Diskus
Data on the safety of the use of Advair Diskus during breastfeeding and pregnancy are not enough. Presumably, given the low systemic absorption of the active ingredients, when applying therapeutic doses of the drug, Advair Diskus, one should not expect undesired effects on the fetus and the newborn.
During pregnancy and lactation, the appointment of Advair Diskus is possible only by the doctor’s decision after a thorough assessment of the risk-benefit ratio. During pregnancy and lactation, it is recommended that minimal effective doses of Advair Diskus be used for a short period.

Drug Interactions
Advair Diskus should be used with caution combined with beta2-adrenoblockers (simultaneous use of these drugs is allowed only if there are serious indications).
Ritonavir, when combined, increases plasma concentrations and the risk of systemic effects of fluticasone. Simultaneous use of Seretide Diskus with ritonavir is allowed only if the expected benefit exceeds the undesirable systemic effect of corticosteroids.
Caution should be exercised when prescribing Advair Diskus concurrently with erythromycin, ketoconazole and other inhibitors of the cytochrome P450 3A4 system, as these drugs may increase the systemic effect of fluticasone.

Overdose
When using Advair Diskus in doses exceeding recommended, it is possible to develop an overdose of salmeterol or fluticasone.
When overdosage of salmeterol in patients, there is a development of headache, limb tremor and heart rhythm disturbances (in particular, tachycardia).

In acute overdose of fluticasone in patients, a temporary oppression of the hypothalamic-pituitary-adrenal system is possible, which itself passes for several days. With a chronic overdose of fluticasone in patients, it is possible to develop a pronounced suppression of the functions of the adrenal glands. There are data on single cases of development of acute adrenal crisis in chronic overdose of fluticasone. Acute adrenal crisis was noted mainly in children who received high doses of fluticasone for a long time. In this case, patients may develop hypoglycemia with a violation of consciousness and convulsions. It should be borne in mind that to provoke an acute adrenal crisis may be traumas, infectious diseases, surgical interventions and a sharp decrease in the dose of fluticasone.

When developing signs of an overdose of salmeterol, cardioselective beta2-adrenergic blockers are prescribed (it should be taken into account that patients with bronchospasm in the anamnesis are prescribed with beta2-adrenoblockers with caution). If, in connection with an overdose of salmeterol, the withdrawal of Advair Diskus should be prescribed an alternative drug for the treatment of the underlying disease.
To prevent the development of chronic overdose of fluticasone, the patient should be monitored and the dose of Advair Diskus reduced to the minimum effective.

Form of issue
Dosage powder for inhalation Advair Diskus for 60 doses in a blister pack of foil with evenly spaced cells, each of which contains 1 dose. In the cardboard bundle, a plastic device for inhalations with 1 blister pack (60 doses) is inserted.

Storage conditions
The drug Advair Diskus should be stored and transported in the original packaging at a temperature of 15 to 20 degrees Celsius.
The shelf life of the drug Seretid Diskus, if stored, is 1.5 years.

Composition
1 dose of Advair Diskus 50 μg / 100 μg contains:
Salmeterol (in the form of salmeterol xinafoate) – 50 mcg;
Micronized fluticasone propionate – 100 mcg;
Additional Ingredients: lactose.

1 dose of Advair Diskus 50 μg / 250 μg contains:
Salmeterol (in the form of salmeterol xinafoate) – 50 mcg;
Micronized fluticasone propionate 250 μg;
Additional Ingredients: lactose.

1 dose of Advair Diskus 50 μg / 500 μg contains:
Salmeterol (in the form of salmeterol xinafoate) – 50 mcg;
Micronized fluticasone propionate – 500 mcg;
Additional Ingredients: lactose.

Attention!
Description of the drugAdvair Diskus” on this page is a simplified and supplemented version of the official instructions for use. Before purchasing or using the drug, you should consult a doctor and read the annotation approved by the manufacturer.
Information about the drug is provided solely for informational purposes and should not be used as a guide to self-treatment. only the doctor can decide on the appointment of the drug, as well as determine the dose and methods of its use.

Buy Advair Diskus (Adoair) online.

Filed under

Asthma

| Tags:

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Comments are closed.

Categories

Recent Comments

error: Content is protected !!